vs

Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $69.8M, roughly 1.3× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -98.1%, a 482.1% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 21.2%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 53.7%).

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

HIVE vs RIGL — Head-to-Head

Bigger by revenue
HIVE
HIVE
1.3× larger
HIVE
$93.1M
$69.8M
RIGL
Growing faster (revenue YoY)
HIVE
HIVE
+197.4% gap
HIVE
218.6%
21.2%
RIGL
Higher net margin
RIGL
RIGL
482.1% more per $
RIGL
384.0%
-98.1%
HIVE
Faster 2-yr revenue CAGR
HIVE
HIVE
Annualised
HIVE
102.2%
53.7%
RIGL

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
HIVE
HIVE
RIGL
RIGL
Revenue
$93.1M
$69.8M
Net Profit
$-91.3M
$268.1M
Gross Margin
-27.1%
91.5%
Operating Margin
33.2%
Net Margin
-98.1%
384.0%
Revenue YoY
218.6%
21.2%
Net Profit YoY
-234.0%
1769.2%
EPS (diluted)
$-0.38
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIVE
HIVE
RIGL
RIGL
Q4 25
$93.1M
$69.8M
Q3 25
$87.3M
$69.5M
Q2 25
$45.6M
$101.7M
Q1 25
$53.3M
Q4 24
$29.2M
$57.6M
Q3 24
$22.6M
$55.3M
Q2 24
$32.2M
$36.8M
Q1 24
$29.5M
Net Profit
HIVE
HIVE
RIGL
RIGL
Q4 25
$-91.3M
$268.1M
Q3 25
$-15.8M
$27.9M
Q2 25
$35.0M
$59.6M
Q1 25
$11.4M
Q4 24
$68.2M
$14.3M
Q3 24
$80.0K
$12.4M
Q2 24
$-18.3M
$-1.0M
Q1 24
$-8.2M
Gross Margin
HIVE
HIVE
RIGL
RIGL
Q4 25
-27.1%
91.5%
Q3 25
4.7%
93.2%
Q2 25
-13.6%
95.6%
Q1 25
91.7%
Q4 24
-43.7%
89.9%
Q3 24
-66.1%
85.5%
Q2 24
-7.4%
92.4%
Q1 24
93.1%
Operating Margin
HIVE
HIVE
RIGL
RIGL
Q4 25
33.2%
Q3 25
40.9%
Q2 25
60.1%
Q1 25
23.9%
Q4 24
28.9%
Q3 24
25.4%
Q2 24
1.2%
Q1 24
-23.6%
Net Margin
HIVE
HIVE
RIGL
RIGL
Q4 25
-98.1%
384.0%
Q3 25
-18.1%
40.2%
Q2 25
76.8%
58.6%
Q1 25
21.5%
Q4 24
233.2%
24.9%
Q3 24
0.4%
22.5%
Q2 24
-56.7%
-2.8%
Q1 24
-27.9%
EPS (diluted)
HIVE
HIVE
RIGL
RIGL
Q4 25
$-0.38
$14.11
Q3 25
$-0.07
$1.46
Q2 25
$0.18
$3.28
Q1 25
$0.63
Q4 24
$0.52
$0.82
Q3 24
$0.00
$0.70
Q2 24
$-0.17
$-0.06
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIVE
HIVE
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$559.3M
$391.5M
Total Assets
$624.0M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIVE
HIVE
RIGL
RIGL
Q4 25
$155.0M
Q3 25
$137.1M
Q2 25
$108.4M
Q1 25
$77.1M
Q4 24
$40.5M
$77.3M
Q3 24
$31.7M
$61.1M
Q2 24
$49.1M
Q1 24
$49.5M
Total Debt
HIVE
HIVE
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
HIVE
HIVE
RIGL
RIGL
Q4 25
$559.3M
$391.5M
Q3 25
$624.6M
$117.6M
Q2 25
$560.5M
$81.9M
Q1 25
$18.6M
Q4 24
$430.9M
$3.3M
Q3 24
$275.5M
$-14.6M
Q2 24
$268.6M
$-29.9M
Q1 24
$-31.7M
Total Assets
HIVE
HIVE
RIGL
RIGL
Q4 25
$624.0M
$513.6M
Q3 25
$693.0M
$242.5M
Q2 25
$628.7M
$206.7M
Q1 25
$176.0M
Q4 24
$478.6M
$164.0M
Q3 24
$334.7M
$139.4M
Q2 24
$128.4M
Q1 24
$126.5M
Debt / Equity
HIVE
HIVE
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIVE
HIVE
RIGL
RIGL
Operating Cash FlowLast quarter
$46.0M
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIVE
HIVE
RIGL
RIGL
Q4 25
$46.0M
$22.0M
Q3 25
$-10.6M
$24.0M
Q2 25
$10.2M
$30.5M
Q1 25
$-893.0K
Q4 24
$-28.5M
$14.5M
Q3 24
$-2.2M
$21.7M
Q2 24
$-4.4M
$302.0K
Q1 24
$-5.0M
Free Cash Flow
HIVE
HIVE
RIGL
RIGL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-55.5M
Q3 24
$-34.7M
Q2 24
Q1 24
FCF Margin
HIVE
HIVE
RIGL
RIGL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-189.9%
Q3 24
-153.4%
Q2 24
Q1 24
Capex Intensity
HIVE
HIVE
RIGL
RIGL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
92.5%
Q3 24
143.9%
Q2 24
Q1 24
Cash Conversion
HIVE
HIVE
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.29×
0.51×
Q1 25
-0.08×
Q4 24
-0.42×
1.01×
Q3 24
-26.94×
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons